Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer
نویسندگان
چکیده
منابع مشابه
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.
The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.
متن کاملVEGF-targeted therapy in metastatic renal cell carcinoma.
PURPOSE To review the biology of renal cell carcinoma (RCC) and the clinical results of vascular endothelial growth factor (VEGF) blockade in metastatic RCC. METHODS A review of relevant published literature regarding VEGF, von Hippel-Lindau (VHL) gene inactivation, and VEGF overexpression in RCC was performed. Further, a review of the mechanism, toxicity, and clinical development of VEGF-tar...
متن کاملOsteoclast-targeted therapy for metastatic prostate cancer
10.2217/14750708.5.1.63 © 20 Bone metastases and skeletal complications are major causes of morbidity in men with prostate cancer. Despite the osteoblastic appearance of bone metastases on imaging studies, patients with bone metastases have elevated markers of bone resorption, indicative of high osteoclast activity. Indeed, increased osteoclast activity is independently associated with higher r...
متن کاملMetastatic renal cell cancer
Targeted therapy is the treatment of choice in patients with metastatic renal cell cancer (mRCC) at most institutions although a combination of cytokine therapy and targeted therapy still is being investigated. Morphological size-based criteria (RECIST) has failed in monitoring the effect of targeted therapy in patients with mRCC, as successful therapy often does not result in a decrease in tum...
متن کاملTargeted Therapy for Metastatic Renal Carcinoma: an Update
Conventional chemotherapy is associated with poor outcomes in metastatic renal cell carcinoma (RCC). Advances in the understanding of tumor molecular biology and the implementation of new drugs that target these molecular pathways have increased the arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly describe the latest data on targeted therapies used in the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular and Clinical Oncology
سال: 2017
ISSN: 2049-9450,2049-9469
DOI: 10.3892/mco.2017.1371